Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tacrolimus + ripertamab
- Development stage
- Phase 3
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tacrolimus + ripertamab is a combination therapy being investigated for the treatment of kidney diseases, particularly minimal change disease (MCD) and membranous nephropathy. Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation, while ripertamab is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody similar to rituximab. The combination aims to provide higher remission rates, lower recurrence rates, and fewer side effects compared to standard treatments for these conditions.
02
Targets
Beyond the preview
Go deeper on tacrolimus + ripertamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tacrolimus + ripertamab.